|
Over the past 5 years, small molecule tyrosine kinase inhibitors have been
successfully introduced as new cancer therapeutics. The pioneering work with the
ABL inhibitor imatinib (Glivec, Gleevec) was rapidly extended to other types of
leukemias as well as solid tumors, which stimulated the development of a variety
of new tyrosine kinase inhibitors. Unfortunately, oncogenic tyrosine kinases
seem to have little problem to develop resistance to these inhibitors, and there
is good evidence that this is not limited to imatinib, but also occurs with
other inhibitors, such as FLT3 and EGFR inhibitors.
New! Sign up for local CML support group meetings in your local community at http://cml.meetup.com Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com CML (Chronic Myelogenous Leukemia Support List) --------------------------------- Part Of CMLHope.Com An International Community Of CML Patients For more information: http://cmlhope.com Post Message: [email protected] Subscribe: [EMAIL PROTECTED] Unsubscribe: [EMAIL PROTECTED] Change To No Mail/Web: [EMAIL PROTECTED] Change To Digest: [EMAIL PROTECTED] Change To Email: [EMAIL PROTECTED] List Help: [EMAIL PROTECTED] CML Group Web Site http://groups.yahoo.com/group/CML Yahoo! Groups Links
|
